Related Experiment Video

Updated: Jun 27, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and

Chen-May Wong1, Yu Ko, Alexandre Chan

  • 1Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.

The Annals of Pharmacotherapy
|November 27, 2008
PubMed
Abstract

Insights

Drug-drug interactions (DDIs) involving oral anticancer agents are common. This study found significant inconsistencies between two major drug interaction compendia, highlighting the need for standardization.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Safety

Background:

  • Oral anticancer agents are increasingly used for cancer treatment.
  • Patients on oral chemotherapy face a high risk of drug-drug interactions (DDIs).

Purpose of the Study:

  • To develop drug interaction profiles for clinically significant DDIs with oral anticancer agents.
  • To evaluate agreement between Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX for these DDIs.

Main Methods:

  • Literature reviews were used to create DDI profiles.
  • Two major drug interaction compendia were compared for DDI listings, severity, and evidence ratings.
  • Spearman correlation assessed severity rating agreement.

Main Results:

  • 184 DDIs were identified; 40 met criteria for clinical significance.
  • Significant inconsistencies were found in DDI listings (15.2% DIF only, 46.7% Micromedex only).
  • Severity ratings showed moderate correlation (Spearman's rho = 0.49), with 25.8% disagreement in evidence ratings.

Conclusions:

  • Discrepancies between compendia highlight variability in DDI data.
  • Further research is needed to standardize DDI definitions and classifications for improved patient safety.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...